Evolution of the Average Target: IDEXX Laboratories, Inc.

Evolution of the Target Price: IDEXX Laboratories, Inc.

Changes in Analyst Recommendations: IDEXX Laboratories, Inc.

32e7eb45b99c8ebef6bda01bb.uCGL-A-3y_UetByWPQ8cnt9hLmEdtM0H4xlFiy9A4Zo.wHfkm2zDh5RshmbbBWlDyL0EbzNJjZJBi34B0W0nsdfyftLNdvv8n0bifw~ad078daf9c4b8100bd4ed8d57665e4c4
08-11 Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating MT
08-05 Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792 MT
08-05 Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650 MT
08-05 UBS Adjusts Price Target on IDEXX Laboratories to $670 From $620, Maintains Neutral Rating MT
07-27 Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says MT
07-27 UBS Cuts IDEXX Laboratories Price Target to $620 From $640, Maintains Neutral Rating MT
07-13 Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating MT
05-06 Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $665 From $655 MT
05-06 Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785 MT
04-28 UBS Adjusts Price Target on IDEXX Laboratories to $640 From $730, Maintains Neutral Rating MT
04-27 Jefferies Adjusts Price Target on IDEXX Laboratories to $785 From $820, Maintains Buy Rating MT
04-15 Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target MT
04-14 Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating MT
03-31 Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating MT
02-09 Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating MT
02-05 Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating MT
02-04 Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850 MT
02-03 Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830 MT
02-03 UBS Adjusts IDEXX Laboratories PT to $730 From $750 MT
02-03 Leerink Partners Adjusts Price Target on IDEXX Laboratories to $760 From $785 MT
02-03 BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830 MT
02-03 Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700 MT
12-09 Barclays Initiates IDEXX Laboratories With Overweight Rating, $850 Price Target MT
11-10 Piper Sandler Adjusts Price Target on IDEXX Laboratories to $775 From $700 MT
11-04 UBS Adjusts Price Target on IDEXX Laboratories to $750 From $710, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+23.28%
Average +23.28%
Weighted average by Cap. +23.28%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
550.96USD
Average target price
698.92USD
Spread / Average Target
+26.86%
High Price Target
805.00USD
Spread / Highest target
+46.11%
Low Price Target
470.00USD
Spread / Lowest Target
-14.69%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Barclays
Jefferies & Co.
Citigroup
UBS
Leerink Partners
Rothschild & Co Redburn
Stifel Nicolaus
Piper Sandler
BTIG
Morgan Stanley
JPMorgan Chase
BNP Paribas Exane
BofA Securities
Redburn Atlantic
Goldman Sachs
Atlantic Equities
Credit Suisse
Guggenheim
J.P. Morgan Chase
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
550.96USD
Average target price
698.92USD
Spread / Average Target
+26.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXX Stock
  4. I1DX34 Stock
  5. Consensus IDEXX Laboratories, Inc.